Noradrenergic modulation of risk/reward decision making

Psychopharmacology
David R MontesStan B Floresco

Abstract

Catecholamine transmission modulates numerous cognitive and reward-related processes that can subserve more complex functions such as cost/benefit decision making. Dopamine has been shown to play an integral role in decisions involving reward uncertainty, yet there is a paucity of research investigating the contributions of noradrenaline (NA) transmission to these functions. The present study was designed to elucidate the contribution of NA to risk/reward decision making in rats, assessed with a probabilistic discounting task. We examined the effects of reducing noradrenergic transmission with the α2 agonist clonidine (10-100 μg/kg), and increasing activity at α2A receptor sites with the agonist guanfacine (0.1-1 mg/kg), the α2 antagonist yohimbine (1-3 mg/kg), and the noradrenaline transporter (NET) inhibitor atomoxetine (0.3-3 mg/kg) on probabilistic discounting. Rats chose between a small/certain reward and a larger/risky reward, wherein the probability of obtaining the larger reward either decreased (100-12.5 %) or increased (12.5-100 %) over a session. In well-trained rats, clonidine reduced risky choice by decreasing reward sensitivity, whereas guanfacine did not affect choice behavior. Yohimbine impaired adjustments in d...Continue Reading

References

Aug 15, 1977·European Journal of Pharmacology·J M Cedarbaum, G K Aghajanian
Jan 1, 1982·Journal of Neural Transmission·C Spyraki, H C Fibiger
May 20, 1998·The American Journal of Psychiatry·T SpencerL Seidman
Oct 12, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·B M LiZ T Mei
Aug 16, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·R A AveryA F Arnsten
Nov 15, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Frank P BymasterKenneth W Perry
Jan 28, 2003·Biological Psychiatry·David MichelsonDenái Milton
Jan 1, 1961·Psychopharmacologia·G HOLMBERG, S GERSHON
Sep 16, 2004·Psychological Bulletin·Leonard Green, Joel Myerson
Feb 17, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·William MarrsJ David Jentsch
Jul 19, 2005·Annual Review of Neuroscience·Gary Aston-Jones, Jonathan D Cohen
Aug 30, 2005·Biological Psychiatry·Marcel M van GaalenLouk J M J Vanderschuren
Jul 20, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Emma S J RobinsonTrevor W Robbins
Oct 25, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Xiao-Hua JiBao-Ming Li
Jun 4, 2008·Genes, Brain, and Behavior·C J Wilhelm, S H Mitchell
Aug 1, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jennifer R St Onge, Stan B Floresco
Apr 24, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Sarvin Ghods-SharifiStan B Floresco
Jun 19, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Fiona D ZeebCatharine A Winstanley
Jun 27, 2009·Annual Review of Neuroscience·T W Robbins, A F T Arnsten
Nov 7, 2009·Cerebral Cortex·Jennifer R St Onge, Stan B Floresco
Jan 29, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Andrea BariTrevor W Robbins
May 25, 2010·Psychopharmacology·Jennifer R St OngeStan B Floresco
Sep 22, 2010·Journal of the American Academy of Child and Adolescent Psychiatry·Nao J GamoAmy F T Arnsten
Dec 15, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Hidehiko TakahashiTetsuya Suhara
Jan 26, 2011·Cognitive, Affective & Behavioral Neuroscience·Colin M Stopper, Stan B Floresco
Apr 15, 2011·Biological Psychiatry·Amy F T Arnsten
Jun 10, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Jennifer R St OngeStan B Floresco

❮ Previous
Next ❯

Citations

Oct 26, 2016·Pharmacology, Biochemistry, and Behavior·Justin R YatesSara M Shape
Nov 6, 2018·Behavioural Pharmacology·Shelby L BlaesBarry Setlow
Jan 13, 2019·Psychopharmacology·Aleksandra M HermanTheodora Duka
Jan 14, 2021·Scientific Reports·Nathan A SchneiderHyun-Jae Pi
Mar 3, 2021·Psychopharmacology·Chloe S ChernoffCatharine A Winstanley
Mar 16, 2021·Frontiers in Neuroscience·Hector Bravo-RiveraGregory J Quirk
Aug 17, 2021·Psychological Research·Yudai Takarada, Daichi Nozaki
Oct 28, 2021·Psychological Science·Jörg GrossCarsten K W De Dreu

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Colin M StopperStan B Floresco
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Jennifer R St Onge, Stan B Floresco
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
Jennifer R St OngeStan B Floresco
© 2021 Meta ULC. All rights reserved